Approximately 20% of patients with breast cancer exhibit gene amplification and/or overexpression of human epidermal growth factor receptor 2 (HER2)1, which carries poorer prognosis in terms of risk for relapse and metastasis. This evidence concerns the gene ERBB2 and breast cancer.